109 results
Page 3 of 6
8-K
EX-99.1
9ro9cwuwbsekg96f
13 Jul 16
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES PV-10 DATA DISCUSSED AT 6th EUROPEAN POST-CHICAGO MELANOMA/SKIN CANCER MEETING
12:00am
8-K
bk7kh
29 Jan 15
Provectus Biopharmaceuticals Begins Recruitment for Phase 2 Mechanism of Action Clinical Trial of PH-10 for Psoriasis
12:00am
8-K
EX-99.1
7bjxqty c4
29 Jan 15
Provectus Biopharmaceuticals Begins Recruitment for Phase 2 Mechanism of Action Clinical Trial of PH-10 for Psoriasis
12:00am
8-K
EX-99.1
lbfkuer9pp8y edh
23 Dec 14
Regulation FD Disclosure
12:00am
8-K
EX-99.1
69e65w62xs26ifwt4g3
29 Sep 14
Regulation FD Disclosure
12:00am
8-K
EX-99.1
hozph
8 Jul 14
Provectus Updates Shareholders In Its Annual Ceo Letter
12:00am
8-K
EX-99.2
g1now
23 May 14
Regulation FD Disclosure
12:00am
8-K
EX-99.1
vm1fwxvdtx
24 Mar 14
Provectus Biopharmaceuticals Inc. Submits Application to Fda to Receive Breakthrough Therapy Designation for PV-10 for Treatment of Melanoma
12:00am